-
Mashup Score: 1
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmnH7Q @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/w9tdjsTPLv
-
-
Mashup Score: 0
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for adv. #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. @AttardLab @ucl joins @ashleyrossmdphd @NM_Urology on UroToday > https://t.co/lp4x0TKZzZ https://t.co/45zEqZ5SOX
-
-
Mashup Score: 0
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmnH7Q @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/H7epFpmUKR
-
-
Mashup Score: 1
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmnH7Q @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/26YmQerZiO
-
-
Mashup Score: 0
Marina Parry and Gerhardt Attard join Alicia Morgans in discussing two key studies from the STAMPEDE trial platform, including “Comparison of abiraterone acetate and prednisolone or combination enzalutamide + abiraterone acetate and prednisolone for metastatic hormone-sensitive prostate cancer (mHSPC) starting ADT: overall survival (OS) results of 2 randomized Phase III trials from the STAMPEDE…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Insights from the #STAMPEDE trial platform. @marina_parry & Gerhardt Attard, MD, PhD, FRCP @ucl join @CaPsurvivorship @DanaFarber to discuss two key studies from the STAMPEDE trial platform. #WatchNow on UroToday > https://t.co/P9edl73LhE @AttardLab @Decipher_VCYT https://t.co/IYJHIjGNix
-
-
Mashup Score: 1
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for adv. #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. @AttardLab @ucl joins @ashleyrossmdphd @NM_Urology on UroToday > https://t.co/lp4x0TKZzZ https://t.co/9dpQKzsVNj
-
-
Mashup Score: 3
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmnH7Q @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/UyvpbHwiAZ
-
-
Mashup Score: 2
Among men with high-risk non-metastatic prostate cancer, combination therapy is associated with significantly higher rates of metastasis-free survival compared with ADT alone. Abiraterone acetate with prednisolone should be considered a new standard treatment for this population.
Source: The LancetCategories: Hem/Oncs, Latest HeadlinesTweet-
4/ In 2 #STAMPEDE RCTs: Abiraterone (±enzalutamide) combined with ADT in high risk M0 #PCa⬆️metastasis-free survival, OS, PFS, DSS. Unclear benefit of adding enzalutamide with⬆️toxicity. @AttardLab @Prof_Nick_James @mattsydes @TheLancet @Silke_Gillessen https://t.co/P3wnEMyWre https://t.co/dUSBWs5T74
-
-
Mashup Score: 0
Gerhardt Attard joins Ashley Ross in discussing an ancillary study of the STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced prostate cancer starting ADT with or without abiraterone acetate and prednisolone. The addition of abiraterone acetate and prednisolone to ADT is the standard of care for advanced prostate cancer (metastatic, M1 and high-risk…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
An ancillary study of the #STAMPEDE trial assessing the clinical qualification of transcriptome signatures for advanced #ProstateCancer starting ADT +/- abiraterone acetate and prednisolone. #WatchNow > https://t.co/2NgQkmnH7Q @AttardLab @ashleyrossmdphd @Decipher_VCYT @Veracyte https://t.co/nvVzcLVeJ8
-
Insights from the #STAMPEDE trial platform. @marina_parry & Gerhardt Attard, MD, PhD, FRCP @ucl join @CaPsurvivorship @DanaFarber to discuss two key studies from the STAMPEDE trial platform. #WatchNow on UroToday > https://t.co/P9edl73LhE @AttardLab @Decipher_VCYT https://t.co/0522tAwfyB